In today's edition of Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at Johnson & Johnson, the largest health-care company in the Dow. They discuss the key takeaways from Johnson & Johnson's second-quarter results and look at its main opportunities in the medical device, pharmaceutical, and consumer health-care spaces.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Market Checkup: Johnson & Johnson's Second Quarter
The Motley Fool's health-care show Market Checkup for August 13, 2013.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Vertex Pharmaceuticals and owns shares of Dendreon and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.